Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 23 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

22%

5 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (6)
P 1 (3)
P 2 (2)
P 3 (5)

Trial Status

Completed11
Recruiting5
Unknown3
Active Not Recruiting2
Not Yet Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07023341Phase 3Active Not RecruitingPrimary

A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03723655Phase 2Completed

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

NCT06116968Phase 3CompletedPrimary

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

NCT05489705RecruitingPrimary

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT07021976Phase 3RecruitingPrimary

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT06516068Phase 2Active Not RecruitingPrimary

A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT06856265Not ApplicableNot Yet RecruitingPrimary

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT04783766Phase 1CompletedPrimary

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

NCT06551129RecruitingPrimary

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

NCT06023186RecruitingPrimary

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

NCT06146660RecruitingPrimary

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05879523Phase 1CompletedPrimary

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

NCT06598995Completed

Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy

NCT05174416Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

NCT06354556Phase 1CompletedPrimary

Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects

NCT06224621Not ApplicableUnknownPrimary

Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy

NCT06368037Not ApplicableNot Yet RecruitingPrimary

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

NCT06211595Not ApplicableUnknownPrimary

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

NCT05771987Not ApplicableUnknownPrimary

Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.

NCT05726799Completed

Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach

Scroll to load more

Research Network

Activity Timeline